Drug Profile
AN 9
Alternative Names: Pivaloyloxymethyl Butyrate; PivanexLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Bar-Ilan University
- Class Antineoplastics; Butyrates; Butyric acids
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Liver cancer; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 18 Mar 2005 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
- 18 Mar 2005 Discontinued - Phase-II for Malignant melanoma in USA (Topical)
- 12 Jul 2004 AN 9 is available for licensing (http://www.titanpharm.com)